Holen Sie sich die Stockscreener-App
26.49
6.17%
1.54
Handel nachbörslich:
27.00
0.51
+1.93%
Schlusskurs vom Vortag:
$24.95
Offen:
$25.2
24-Stunden-Volumen:
660.00K
Relative Volume:
0.74
Marktkapitalisierung:
$2.02B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.16M
KGV:
-20.85
EPS:
-1.2702
Netto-Cashflow:
$-69.06M
1W Leistung:
+4.74%
1M Leistung:
-0.86%
6M Leistung:
-7.05%
1J Leistung:
-20.95%
1-Tages-Spanne:
$25.14
$26.62
1-Wochen-Bereich:
$23.65
$26.62
52-Wochen-Spanne:
$14.80
$40.47
Cg Oncology Inc Stock (CGON) Company Profile
Firmenname
Cg Oncology Inc
Sektor
Branche
Telefon
(949) 419-6203
Adresse
400 SPECTRUM CENTER DRIVE, IRVINE
Vergleichen Sie CGON mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
26.49 | 1.90B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2024-06-28 | Eingeleitet | BofA Securities | Buy |
| 2024-02-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Eingeleitet | Goldman | Neutral |
| 2024-02-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cg Oncology Inc Aktie (CGON) Neueste Nachrichten
ETF Analysts See 14% Upside for Humankind US Stock ETF - AInvest
CG Oncology price target lowered to $62 from $63 at BofA - MSN
CG Oncology’s Q2 2025: Clinical Advances and Legal Wins - The Globe and Mail
CG Oncology Inc. Attempts Reversal From Key SupportExpert Verified Stock Trade Ideas Backed by Data - beatles.ru
CG Oncology 2025 Q1 Earnings Net Loss Widens Sharply - AInvest
CG Oncology shares rise 1.64% intraday after reporting positive earnings and clinical trial results. - AInvest
CG Oncology's Q2 2025: Balancing Burn Rate and Breakthroughs in the Race for Bladder Cancer Innovation - AInvest
Cg Oncology (CGON) Q2 Loss Widens 93% - The Motley Fool
Cg Oncology (CGON) Q2 Loss Widens 93% - Nasdaq
Earnings Flash (CGON) CG Oncology Posts Q2 Net Loss $0.54 a Share, vs. FactSet Est of $0.46 Loss - MarketScreener
CG Oncology reports Q2 EPS (54c), consensus (44c) - TipRanks
CG Oncology Reports Q2 Financials, Announces BOND-003 Durability Data. - AInvest
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Globe and Mail
How King & Spalding Beat $2B Claim In Biopharma Fight - Law360
Is CG Oncology Inc. a good long term investmentSuperior return velocity - Jammu Links News
Does CG Oncology Inc. stock perform well during market downturnsGet ahead with breakthrough trading ideas - Jammu Links News
What analysts say about CG Oncology Inc. stockInvest confidently with real-time market updates - Jammu Links News
How does CG Oncology Inc. generate profit in a changing economyBreakthrough profit margins - Jammu Links News
CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial - MSN
When is CG Oncology Inc. stock expected to show significant growthInvest confidently with real-time data analysis - Jammu Links News
What are the latest earnings results for CG Oncology Inc.Breakthrough investment results - Jammu Links News
Should I hold or sell CG Oncology Inc. stock in 2025Discover stocks with explosive potential - Jammu Links News
How strong is CG Oncology Inc. company’s balance sheetUnlock expert market analysis instantly - Jammu Links News
What is the risk reward ratio of investing in CG Oncology Inc. stockInvest smarter with advanced market data - Jammu Links News
What makes CG Oncology Inc. stock price move sharplyFree Stock Market Query - Jammu Links News
How to interpret RSI for CG Oncology Inc. stockStock Entry Point Planner with Volume Spike - Newser
Applying big data sentiment scoring on CG Oncology Inc.Free Weekly Setup With 3x Return Potential - Newser
CG Oncology Inc. stock trend outlook and recovery pathTrade Safety Matrix for Conservative Traders - Newser
How volatile is CG Oncology Inc. stock compared to the marketAdvanced Screener Report With Low Risk - Jammu Links News
Why is CG Oncology Inc. stock attracting strong analyst attentionRetirement Planning Forecasts Backed By Experts - Jammu Links News
Building trade automation scripts for CG Oncology Inc.Free Pattern Detection for Entry Confirmation - Newser
What recovery options are there for CG Oncology Inc.Swing Gain Strategy with Entry Forecast - Newser
Comparing CG Oncology Inc. in custom built stock radarsShort-Term Bounce Forecast for Oversold Stocks - Newser
New Product Launches: Will They Boost CG Oncology Inc. Stock in 2025Daily Market Momentum and Pressure Analysis - Newser
ANI Pharmaceuticals Challenges Court Verdict on Royalty Payment Agreement - AInvest
Can CG Oncology Inc. stock recover from recent declineSecure Entry Point Finder with Analysis - Newser
11 Best Future Stocks to Buy Now - Insider Monkey
CG Oncology Soars 10.41% Post Legal Win - AInvest
Options Data Show Bullish Bias in CG Oncology Inc.Early Entry Picks Before News Breakout Reviewed - metal.it
CG Oncology wins Delaware jury trial against ANI Pharmaceuticals By Investing.com - Investing.com South Africa
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals - The Manila Times
CG Oncology Secures Major Legal Victory: Court Rules No 5% Royalties on Promising Bladder Cancer Drug - Stock Titan
Why CG Oncology Inc. stock attracts strong analyst attentionFree Low Risk Equity Screener With Results - Newser
How CG Oncology Inc. stock performs during market volatilityWeekly Setup Summary for Risk Controlled Trades - Newser
Finanzdaten der Cg Oncology Inc-Aktie (CGON)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):